Kieran Lockhart, Jun, 15 2025
Immunovant’s Phase II trials saw batoclimab outperform in both myasthenia gravis and CIDP, with further promise in Graves’ disease. Now, the company is pushing its new asset, IMVT-1402, into more advanced trials, aiming to set a new standard for autoimmune disease treatment.
Categories:
Tags:
Kieran Lockhart, May, 22 2025
Gepotidacin, a first-in-class oral antibiotic, has shown a 93% success rate against drug-resistant gonorrhea in a large phase 3 trial, rivalling existing treatments. Oral dosing could boost accessibility, while parallel discoveries target resistant strains. The WHO urges urgent action as resistant gonorrhea becomes harder to treat.
Categories:
Tags:
Kieran Lockhart, Feb, 16 2025
British model Danielle Lloyd has shared her personal battle with skin cancer, stressing how important it is to catch such issues early. On February 16, 2025, she encouraged everyone to be on the lookout for unusual changes in their skin and to seek medical advice promptly. Her story is a strong reminder of the increasing need for skincare education.
Categories:
Tags:
